Jafron Biomedical Co Ltd - Asset Resilience Ratio
Jafron Biomedical Co Ltd (300529) has an Asset Resilience Ratio of 39.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Jafron Biomedical Co Ltd (300529) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Jafron Biomedical Co Ltd's Asset Resilience Ratio has changed over time. See 300529 net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Jafron Biomedical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300529 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.16 Billion | 39.15% |
| Total Liquid Assets | CN¥2.16 Billion | 39.15% |
Asset Resilience Insights
- Very High Liquidity: Jafron Biomedical Co Ltd maintains exceptional liquid asset reserves at 39.15% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Jafron Biomedical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jafron Biomedical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Annual Asset Resilience Ratio for Jafron Biomedical Co Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Jafron Biomedical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | CN¥61.82K ≈ $9.05K |
CN¥5.41 Billion ≈ $791.50 Million |
-11.02pp |
| 2024-12-31 | 11.02% | CN¥593.07 Million ≈ $86.79 Million |
CN¥5.38 Billion ≈ $787.77 Million |
+7.90pp |
| 2021-12-31 | 3.12% | CN¥150.01 Million ≈ $21.95 Million |
CN¥4.81 Billion ≈ $703.87 Million |
-4.57pp |
| 2016-12-31 | 7.69% | CN¥100.00 Million ≈ $14.63 Million |
CN¥1.30 Billion ≈ $190.21 Million |
-- |
About Jafron Biomedical Co Ltd
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machi… Read more